Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-001574-29
    Sponsor's Protocol Code Number:D967VC00001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-05-24
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-001574-29
    A.3Full title of the trial
    A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
    Studio di fase ll, Multicentrico, in Aperto per Valutare l’Efficacia e la Sicurezza di Trastuzumab Deruxtecan (T-DXd, DS-8201a) per il Trattamento di Tumori Selezionati che esprimono HER2 (DESTINY PanTumour02)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing Tumors
    Studio per valutare l’efficacia, la sicurezza, la tollerabilità di Trastuzumab Deruxtecan in pazienti con tumori selezionati che esprimono HER2
    A.3.2Name or abbreviated title of the trial where available
    DESTINY-PanTumor02
    DESTINY-PanTumor02
    A.4.1Sponsor's protocol code numberD967VC00001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorASTRAZENECA AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstrazeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca
    B.5.2Functional name of contact pointInformation Center
    B.5.3 Address:
    B.5.3.1Street AddressNA
    B.5.3.2Town/ cityNA
    B.5.3.3Post codeNA
    B.5.3.4CountryUnited States
    B.5.6E-mailinformation.center@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTrastuzumab Deruxtecan
    D.3.2Product code [DS-8201a]
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTrastuzumab deruxtecan
    D.3.9.1CAS number 1599440-13-7
    D.3.9.2Current sponsor codeDS-8201a
    D.3.9.3Other descriptive nameTrastuzumab deruxtecan
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.
    Trattamento di tumori solidi selezionati, localmente avanzati, non resecabili, metastatici, che esprimono HER2 (IHC 3+ or IHC 2+) and HER2 low (1+), per cui non esiste un’opzione terapeutica alternativa
    E.1.1.1Medical condition in easily understood language
    Patients with Selected HER2 Expressing Tumors.
    Trattamento di tumori che esprimono HER2
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10029104
    E.1.2Term Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of T-DXd in patients with metastatic or unresectable tumors in selected HER2 expressing tumor types.
    Valutare l'efficacia di T-DXd in pazienti con tumori metastatici o non resecabili che esprimono HER2
    E.2.2Secondary objectives of the trial
    - To further assess the efficacy of T-DXd in patients with metastatic or unresectable tumors in selected HER2-expressing tumor types
    - To assess the safety and tolerability of T-DXd
    - To assess the PK of T-DXd, total anti-HER2 antibody and MAAA-1181 in serum
    - To investigate the immunogenicity of T-DXd
    - Per valutare ulteriormente l'efficacia di T-DXd in pazienti con tumori metastatici o non resecabili in tipi di tumori selezionati che esprimono HER2
    - Valutare la sicurezza e la tollerabilità di T-DXd
    - Per valutare la PK di T-DXd, anticorpo anti-HER2 totale e MAAA-1181 nel siero
    - Studiare l'immunogenicità di T-DXd
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Locally advanced, unresectable, or metastatic disease based on most recent imaging.
    • The respective cohorts for patient inclusion are:
    - Cohort 1: Biliary tract cancer
    - Cohort 2: Bladder cancer
    - Cohort 3: Cervical cancer
    - Cohort 4: Endometrial cancer
    - Cohort 5: Epithelial ovarian cancer
    - Cohort 6: Pancreatic cancer
    - Cohort 7: Rare tumors: This cohort will consist of patients with tumors that express HER2, excluding the tumors mentioned above, and breast, non-small cell lung cancer, gastric cancer, and colorectal cancer.
    • Progressed following prior treatment or who have no satisfactory alternative treatment option.
    • Prior HER2 targeting therapy is permitted.
    • HER2 expression for eligibility may be based on local or central assessment.
    • Has measurable target disease assessed by the Investigator based on RECIST version 1.1.
    • Has protocol- defined adequate organ function including cardiac, renal and hepatic function.
    • Malattia localmente avanzata, non resecabile o metastatica sulla base delle immagini più recenti.
    • Le rispettive coorti per l'inclusione dei pazienti sono:
    - Coorte 1: Tumori del tratto biliare
    - Coorte 2: Tumore della vescica
    - Coorte 3: Tumore della cervice
    - Coorte 4: Tumore dell’endometrio
    - Coorte 5: Tumore delle ovaie
    - Coorte 6: Tumore del pancreas
    - Coorte 7: Tumori rari : questa coorte sarà composta da pazienti con tumori che esprimono HER2, esclusi i tumori sopra menzionati, e tumore al seno, tumore del polmone non a piccole cellule, tumore gastrico e tumore del colon-retto.
    • Progressione dopo un trattamento precedente o mancanza di opzioni terapeutiche alternative
    • È consentita una precedente terapia di targeting HER2.
    • L' elegibilità può essere basata su una valutazione locale o centrale dell'espressione di HER2
    • Presenza di malattia target valutata dallo sperimentatore sulla base della versione RECIST 1.1.
    • Funzione organica adeguatamente definita dal protocollo, inclusa la funzione cardiaca, renale ed epatica.
    E.4Principal exclusion criteria
    • Uncontrolled intercurrent illness
    • History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening
    • Lung-specific intercurrent clinically significant severe illnesses
    • Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals
    • Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART
    • Known Somatic DNA mutation of HER2 (ERBB2) without tumoral HER2 protein expression.
    • Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, adenocarcinoma of the gastric body or gastro-esophageal junction, or non-small cell lung cancer.
    • Malattia intercorrente incontrollata
    • Storia di polmonite non infettiva / ILD, ILD in corso o sospetta ILD che non può essere esclusa dall'Imaging Screening
    • Malattie gravi intercorrenti clinicamente significative specifiche del polmone
    • Infezione non controllata che richiede antibiotici per via endovenosa (IV), antivirali o antimicotici
    • Versamento pleurico, ascite o versamento pericardico che richiede drenaggio, shunt peritoneale o Cell-free and Concentrated Ascites Reinfusion Therapy (CART)
    • Mutazione nota del DNA somatico di HER2 (ERBB2) senza espressione della proteina HER2 tumorale.
    • Diagnosi primaria di adenocarcinoma della mammella, del colon o del retto, del corpo gastrico o della giunzione gastro-esofagea o carcinoma polmonare non a piccole cellule.
    E.5 End points
    E.5.1Primary end point(s)
    Objective Response Rate (ORR).
    Il tasso di risposte obiettive (ORR)
    E.5.1.1Timepoint(s) of evaluation of this end point
    An average of approximately 12 months.
    Una media di circa 12 mesi.
    E.5.2Secondary end point(s)
    1) Duration of response (DoR).
    2) Disease control rate (DCR).
    3) Progression free survival (PFS).
    4) Proportion of patients alive and progression-free at 6 months and 12 months.
    5) Overall survival (OS).
    6) Proportion of patients alive at 6 months and 12 months.
    7) Occurrence of adverse events (AEs) and serious adverse events (SAEs).
    8) Pharmacokinetics (PK) assessed by serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181.
    9) The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd.
    1) Durata della risposta (DoR).
    2) Tasso di controllo della malattia (DCR).
    3) Sopravvivenza libera da progressione (PFS).
    4) Proporzione di pazienti vivi e liberi da progressione a 6 mesi e 12 mesi.
    5) Sopravvivenza globale (OS).
    6) Proporzione di pazienti vivi a 6 mesi e 12 mesi.
    7) Presenza di eventi avversi (EA) ed eventi avversi gravi (SAEs).
    8) Farmacocinetica (PK) valutata in base alla concentrazione sierica di T-DXd, anticorpo totale anti-HER2 e MAAA-1181.
    9) L'immunogenicità di T-DXd valutata dalla presenza di ADA per T-DXd.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1) An average of approximately 18 months.
    2) An average of approximately 18 months.
    3) An average of approximately 18 months.
    4) Up to 12 months.
    5) An average of approximately 30 months.
    6) Up to 12 months.
    7) An average of approximately 24 months.
    8) An average of approximately 24 months.
    9) An average of approximately 24 months.
    1) Una media di circa 18 mesi.
    2) Una media di circa 18 mesi.
    3) Una media di circa 18 mesi.
    4) Fino a 12 mesi.
    5) Una media di circa 30 mesi.
    6) Fino a 12 mesi.
    7) Una media di circa 24 mesi.
    8) Una media di circa 24 mesi.
    9) Una media di circa 24 mesi.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    NA
    NA
    E.8.2.4Number of treatment arms in the trial7
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA45
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    India
    Korea, Republic of
    Russian Federation
    Taiwan
    Thailand
    United States
    Belgium
    France
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    Czechia
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study (“study completion”) is defined as the date of the last protocol-specified visit/assessment (including telephone contact) for the last participant in the study.
    La fine dello studio ("conclusione dello studio") è definita come la data dell'ultima visita / valutazione stabilita dal protocollo (incluso il contatto telefonico) per l'ultimo partecipante allo studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 140
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 140
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 111
    F.4.2.2In the whole clinical trial 280
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No intervention is planned after the end of the study. However, provisions will be in place for patients still ongoing at the end of the study to continue to receive IP if, in the opinion of the Investigator, they are continuing to receive benefit from treatment.
    Non è previsto nessun intervento dopo la fine dello studio. Tuttavia, saranno previste disposizioni affinché i pazienti alla fine dello studio possano continuare a ricevere il farmaco se, secondo lo sperimentatore, continuano a ricevere benefici dal trattamento.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-02-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-11-18
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 10:02:32 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA